During the Phase III BROOKLYN trial, patients were randomly assigned in a 2:1 ratio to receive either obicetrapib 10mg or a ...
SARS-CoV-2 disrupts cholesterol metabolism by using its ORF3a protein to sequester cholesterol in lysosomes, reducing BMP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback